Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma

DSpace Repository

Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma

Author: Ascierto, Paolo A.; Dummer, Reinhard; Gogas, Helen J.; Flaherty, Keith T.; Arance, Ana; Mandala, Mario; Liszkay, Gabriella; Garbe, Claus; Schadendorf, Dirk; Krajsova, Ivana; Gutzmer, Ralf; de Groot, Jan Willem B.; Loquai, Carmen; Gollerkeri, Ashwin; Pickard, Michael D.; Robert, Caroline
Tübinger Autor(en):
Garbe, Claus
Published in: European Journal of Cancer (2019), Bd. 126, S. 33-44
Verlagsangabe: Elsevier Sci Ltd
Language: English
Full text: http://dx.doi.org/10.1016/j.ejca.2019.11.016
ISSN: 1879-0852
DDC Classifikation: 610 - Medicine and health
Dokumentart: Artikel
Show full item record

This item appears in the following Collection(s)